CareDx Analyst Price Targets - Benzinga

CareDx Inc

CDNANASDAQ

Trade with Public

Trade with Public

$66.64

1.642.53%

마지막 업데이트: Oct 1, 1:45 PM

$65.30

0.300.46%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

CareDx Analyst Price Targets - Benzinga

CareDx Analyst Price Targets

Wall Street analyst price targets and consensus rating for CareDx (CDNA).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

5Buy

3Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$39Upside to Avg. PT-42.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	BTIG	Mark Massaro	PT Raise	Buy	$60→$74
Sep 2, 2026	Canaccord Genuity	Kyle Mikson	Initiate	Buy	$65
Aug 6, 2026	BTIG	Mark Massaro	PT Raise	Buy	$45→$60
Jul 31, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Neutral	$46
Jul 16, 2026	BTIG	Mark Massaro	PT Raise	Buy	$28→$45
Apr 29, 2026	BTIG	Mark Massaro	PT Raise	Buy	$26→$28
Feb 26, 2026	BTIG	Mark Massaro	PT Raise	Buy	$25→$26
Feb 25, 2026	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$18→$21
Dec 15, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$14→$18
Nov 6, 2025	BTIG	Mark Massaro	PT Raise	Buy	$22→$25
Sep 23, 2025	BTIG	Mark Massaro	Maintained	Buy	$22
Sep 12, 2025	BTIG	Mark Massaro	Maintained	Buy	$22
Aug 26, 2025	William Blair	Andrew Brackmann	Initiate	Market Perform	—
Aug 8, 2025	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$19→$14
Jul 18, 2025	Craig-Hallum	Connor Chamberlain	PT Cut	Buy	$40→$26
May 5, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$40
May 5, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Neutral	$25
Apr 17, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Buy	$34→$26
Mar 3, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Neutral	$26→$25
Feb 27, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$40

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on CareDx, Raises Price Target to $74

BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $60 to $74.

Benzinga Newsdesk

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.

Vandana Singh

PRO
Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65

Canaccord Genuity analyst Kyle Mikson initiates coverage on CareDx (NASDAQ:CDNA) with a Buy rating and announces Price Target of $65.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on CareDx, Raises Price Target to $60

BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $45 to $60.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $46 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral and maintains $46 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on CareDx, Raises Price Target to $45

BTIG analyst Mark Massaro maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $28 to $45.

Benzinga Newsdesk